{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:04:32Z","timestamp":1790805872948,"version":"4.1.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1097\/md.0000000000006338","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T12:36:47Z","timestamp":1489581407000},"page":"e6338","source":"Crossref","is-referenced-by-count":49,"title":["Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome"],"prefix":"10.1097","volume":"96","author":[{"given":"Alice","family":"Gustavsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillemor","family":"Skattum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grethe","family":"Bergseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorg","family":"Lorentzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngvar","family":"Floisand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidar","family":"Bosnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom Eirik","family":"Mollnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Barratt-Due","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-43-20210309","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R2-43-20210309","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2011-03-344671","article-title":"A novel pathway for human endothelial cell activation by antiphospholipid\/anti-beta2 glycoprotein I antibodies","volume":"119","author":"Allen","year":"2012","journal-title":"Blood"},{"key":"R3-43-20210309","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"key":"R4-43-20210309","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1177\/0961203314546022","article-title":"Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies","volume":"23","author":"Romay-Penabad","year":"2014","journal-title":"Lupus"},{"key":"R5-43-20210309","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos","year":"2013","journal-title":"N Engl J Med"},{"key":"R6-43-20210309","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cll.2013.01.003","article-title":"Catastrophic antiphospholipid syndrome: diagnosis and management in pregnancy","volume":"33","author":"Gomez-Puerta","year":"2013","journal-title":"Clin Lab Med"},{"key":"R7-43-20210309","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1177\/0961203314540764","article-title":"Catastrophic antiphospholipid syndrome: task force report summary","volume":"23","author":"Cervera","year":"2014","journal-title":"Lupus"},{"key":"R8-43-20210309","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/rheumatology\/kew040","article-title":"Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome","volume":"55","author":"Barratt-Due","year":"2016","journal-title":"Rheumatology (Oxford"},{"key":"R9-43-20210309","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Medicine (Baltimore"},{"key":"R10-43-20210309","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.berh.2016.07.004","article-title":"Catastrophic antiphospholipid syndrome: the current management approach","volume":"30","author":"Rodriguez-Pint\u00f3","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R11-43-20210309","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1160\/TH14-03-0191","article-title":"Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study","volume":"112","author":"Ruffatti","year":"2014","journal-title":"Thromb Haemost"},{"key":"R12-43-20210309","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.imbio.2014.11.003","article-title":"Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn","volume":"220","author":"Hallstensen","year":"2015","journal-title":"Immunobiology"},{"key":"R13-43-20210309","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"key":"R14-43-20210309","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.imbio.2011.07.027","article-title":"Off to a slow start: under-development of the complement system in term newborns is more substantial following premature birth","volume":"217","author":"McGreal","year":"2012","journal-title":"Immunobiology"},{"key":"R15-43-20210309","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/0961203309347794","article-title":"Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome","volume":"19","author":"Bramham","year":"2010","journal-title":"Lupus"},{"key":"R16-43-20210309","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R17-43-20210309","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1634\/theoncologist.2008-0086","article-title":"FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Dmytrijuk","year":"2008","journal-title":"Oncologist"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:45:31Z","timestamp":1620960331000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201703170-00043"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006338","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}